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In this article of EBioMedicine Francisco García-del Portillo and col-
leagues report findings that shine a new light on a bacterial mecha-
nism responsible for relapse from antibiotic treatment, and pave the
way for developing new drugs to treat enteric fever with reduced
relapse [1].
Due to the emergence of resistance to chloramphenicol in the
19900s and more recently to fluoroquinolones, third generation ceph-
alosporins (b-lactam antibiotics), along with azithromycin, are now
the treatments of choice for enteric fever [2]. Resistance to cephalo-
sporins is currently relatively low for S. Typhi and S. Paratyphi A, the
causative agents of enteric fever, but as much as 17% of cases treated
with this class of antibiotic end with relapse [3]. Relapse not only
increases morbidity and mortality to enteric fever, but may also con-
tribute to the emergence of resistance to this important first choice
drug. Indeed, the first reports of resistance to third generation cepha-
losporins in addition to multi-drug resistance affecting other drug
choices, a profile called extensively drug resistant (XDR), was
reported in outbreaks in India and Pakistan in 2016 [4]. The emer-
gence of the XDR profile is a serious escalation in the potential lethal-
ity of enteric fever in the coming years.
The processes leading to relapse are not fully understood, but
have been linked to poor access of the drug to the intracellular com-
partment or survival of a fraction of a slow growing pathogen popula-
tion due to persistence or heteroresistance [5,6]. While persistence is
loosely defined as when a fraction of the population survives expo-
sure to a drug, heteroresistance is more specifically a phenomenon
where a portion of the population exhibits a temporary increase in
resistance to a drug [7]. The study by García-del Portillo and col-
leagues describes a distinct mechanism that could explain relapse in
Salmonella infection after treatment with the b-lactam antibioticDOI of original article: http://dx.doi.org/10.1016/j.ebiom.2020.102771.
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seem to be limited to a subset of the population. Instead, adaptation
to the intracellular environment resulted in an increased resistance
to b-lactam antibiotics, including a cephalosporin, ceftriaxone.
Previous work by the same group identified PBP3SAL, a paralog of
the penicillin binding protein PBP3, that was absent form closely
related bacterial species. PBPs are essential proteins involved in pepti-
doglycan synthesis, but are also targets for b-lactam antibiotics that
mimic the peptidoglycan subunits and act as a suicide substrate by
covalently binding the catalytic site. PBP3SAL differs from PBP3 in two
major aspects, it is specifically involved in cell division in the environ-
ment of the host cell phagosome, and has a reduced affinity to b-lactam
antibiotics [8]. The current study shows that PBP3SAL replaces PBP3 in
intracellular Salmonella during infection, and importantly, that Salmo-
nella that were unable to express the alternative PBP3SAL did not cause
relapse in experimentally infected mice treated with the b-lactam anti-
biotic ceftriaxone, a third-generation cephalosporin.
An important message to be taken from this study is that com-
monly used assays to determine antimicrobial resistance are not
capable of identifying resistance resulting from adaptation that occur
specifically in the host. This is a potentially confounding factor for the
surveillance of resistance to a wide range of antibiotics used to treat a
broad array of bacterial pathogens. Currently, most studies on antimi-
crobial resistance of bacterial pathogens focus on resistance under
defined culture conditions that do not mimic conditions inside the
host. The emergence of resistance may go unnoticed by standard sur-
veillance in diagnostic labs and the opportunity to improve therapies
or clinical management missed. Consequently, there is a need to eval-
uate antimicrobial resistance and the expression of the molecular tar-
get of antibiotics in growth conditions encountered within the host.
Perhaps the most exciting prospect arising from the present study
is the opportunity to develop new antimicrobials that target the
PBP3SAL paralogue expressed by Salmonella during infection, and
therefore lower the rate of relapse. This may be possible by the modi-
fication of existing antibiotics or by screening for novel compounds
capable of killing Salmonella cultured in medium that mimics the
environment in the phagosome of host cells.
The findings of this study also raise important questions about the
function of the alternative PBP proteins in host-pathogen interactions.
It seems unlikely that the PBP3-PBP3SAL adaptive mechanism evolved
as a mechanism of resistance to b-lactam antibiotics, as these com-
pounds are not normally present during infection, except as a result ofder the CC BY-NC-ND license. (http://creativecommons.org/licenses/by-nc-nd/4.0/)
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likely to be an inadvertent result of adaptation to the intracellular life-
style. The authors speculate that the PBP3-PBP3SAL mechanism may be
associated with specific adaptation to replicate more slowly in the
intracellular compartment in the host, to avoid excessive damage to
the host. Such adaptation would be expected to affect the likelihood of
transmission by extending the duration of infection [9].
The presence of this adaptive mechanism in Salmonella and its
absence in the closely related bacterium Escherichia coli that evolved
predominantly as an extracellular commensal of the intestinal tract
of mammals, is consistent with its acquisition by Salmonella as an
important event in the evolution of this enteric pathogen. Interest-
ingly, alternative PBPs encoded on plasmids along with other antimi-
crobial resistance genes have been reported in other species such as
the Enterococci [10], suggesting one possible origin of PBP paralogues
by horizontal gene transfer.
This study marks a significant advancement in the understanding
of relapse following cephalosporin treatment of enteric fever and iden-
tifies a potential target for improved therapies through the discovery
of a previously unrecognised Salmonella adaptation within the host.
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